Age-associated disparity in phagocytic clearance affects the efficacy of cancer nanotherapeutics.
Wang Y, Deng W, Lee D, Yan L, Lu Y, Dong S, Huntoon K, Antony A, Li X, Ye R, Zhao Y, Zhao F, Schrank BR, Ha J, Kang M, Yang M, Gong P, Lorenzi PL, Tan L, Gallup TD, Tang SK, Yang Z, Li J, Sanford NN, Wang H, Kim BYS, Jiang W.
Wang Y, et al.
Nat Nanotechnol. 2024 Feb;19(2):255-263. doi: 10.1038/s41565-023-01502-3. Epub 2023 Sep 18.
Nat Nanotechnol. 2024.
PMID: 37723279
However, clinical adoption of nanoformulated agents is often hindered by concerns about hepatic uptake and clearance, a process that is not fully understood. Here we show that the antitumour efficacy of cancer nanomedicine exhibits an age-associated disparity. Tumour deliv …
However, clinical adoption of nanoformulated agents is often hindered by concerns about hepatic uptake and clearance, a process that is not …